Aquestive Therapeutics, Inc.

NASDAQ:AQST

Drug Manufacturers - Specialty & Generic

Healthcare
$3.78 +5.08%

+$0.23 today

Market cap
$475.10M
Beta
1.45
P/E (TTM)
-8.3
EPS (TTM)
-$0.56
52W Low $2.93High $7.55

Volume 1.80M

Average 1.51M

AQST Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Aquestive Therapeutics, Inc.NASDAQ: AQST

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 122.61M shares rose 28.4% year over year, ahead of the +23.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +35.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +28.4% holds above the trailing-twelve-month pace of +23.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
122.61M+0.5% QoQ
Last fiscal yearDec 2025
121.97M+40.6% YoY
LTMMar 2026
113.62M+23.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.4%——
1 year+40.6%——
3-year CAGR+35.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
121.97M USD
Year-over-year change
+40.6%
4-year CAGR
+33.8%

Weighted Avg Shares (Diluted) vs competitors

How AQST compares with its peers on the latest reported figures

  • AQST's LTM Mar 2026 weighted avg shares (diluted) of 113.62M shares is the 3rd highest of the 10 companies compared; the peer median is 57.4M shares.
  • Its year-over-year change of +23.3% is the highest of 10, against a peer median of +3.1%.
  • Over three fiscal years its annual growth of +35.8% compares with a peer median of +1.1%.
AQST Competitors Peer median
Weighted Avg Shares (Diluted) for AQST and competitors
Company Period LTM YoY 3-year CAGR
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026172.82M +15.4%+8.4%
ALKSAlkermes plcLTM Sep 2026169.48M +0.9%+1.0%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026113.62M +23.3%+35.8%
VNDAVanda Pharmaceuticals Inc.LTM Mar 202659.11M +1.3%+1.1%
ZVRAZevra Therapeutics, Inc.LTM Mar 202657.44M +16.4%+18.4%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 202657.4M +2.1%-2.9%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202647.36M -8.0%-2.8%
COLLCollegium Pharmaceutical, Inc.LTM Mar 202639.57M +3.1%+5.5%
DERMJourney Medical CorporationLTM Mar 202625.01M +17.3%+11.8%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 202614.96M +4.2%+0.9%
Peer median (excluding AQST) 57.4M+3.1%+1.1%

Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue50.83M47.68M50.58M57.56M44.55M
Cost of Revenue14.99M19.39M20.83M17.87M17.15M
Gross Profit35.84M28.29M29.75M39.69M27.39M
Gross Margin70.5%59.3%58.8%69.0%61.5%
Research & Development17.05M17.48M13.1M20.28M17.19M
Selling, General & Admin53.48M52.88M31.75M50.18M79.85M
Operating Expenses70.52M70.36M44.85M70.46M97.04M
Depreciation & Amortization2.96M2.39M1.35M718K559K
EBITDA(45.11M)(39.58M)1.18M(26.62M)(66.13M)
EBITDA Margin-88.8%-83.0%2.3%-46.2%-148.4%
Operating Income(34.68M)(42.07M)(15.1M)(30.77M)(69.65M)
Operating Margin-68.2%-88.2%-29.9%-53.5%-156.4%
Interest Income423K99K16.32M3.44M0
Interest Expense22.46M12.44M7.46M16.82M17.1M
Other Income / Expenses(35.86M)(12.34M)7.48M(13.38M)(14.13M)
Income Before Tax(70.54M)(54.41M)(7.63M)(44.15M)(83.78M)
Pre-Tax Margin-138.8%-114.1%-15.1%-76.7%-188.1%
Income Tax Expense00245K(14K)0
Net Income(70.54M)(54.41M)(7.87M)(44.14M)(83.78M)
Net Margin-138.8%-114.1%-15.6%-76.7%-188.1%
EPS (Basic)(1.85)(1.12)(0.13)(0.51)(0.76)
EPS (Diluted)(1.85)(1.12)(0.13)(0.51)(0.76)
Weighted Avg Shares38.08M48.73M61.26M86.73M121.97M
Weighted Avg Shares (Diluted)38.08M48.73M61.26M86.73M121.97M

Aquestive Therapeutics, Inc.

NASDAQ:AQST

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.